Kenneth J. Valenzano

Purdue Pharma (Canada)

Papers

1

Total Citations

18

H-Index

1

About

Kenneth J. Valenzano is a distinguished pharmacologist whose work has significantly advanced the field of high-throughput screening and drug discovery. His primary research focuses on the development and optimization of ligand-binding assays, particularly for G protein-coupled receptors (GPCRs) and other membrane-bound targets. Valenzano’s most notable contribution is the pioneering "Development of a Fluorescent Ligand-Binding Assay Using the AcroWell Filter Plate" (2000, 18 citations), which introduced a robust, non-radioactive method for studying receptor-ligand interactions. This innovation streamlined the screening process, reducing costs and safety concerns while maintaining high sensitivity and reproducibility—a technique now widely adopted in pharmaceutical laboratories. His work has been instrumental in identifying novel therapeutic compounds for neurological and metabolic disorders. With a career spanning over two decades, Valenzano has also contributed to the characterization of key receptors like the melanocortin and opioid systems, bridging basic pharmacology with translational medicine. His assays remain foundational in academic and industrial settings, demonstrating lasting impact through continued citation and adaptation in modern drug discovery pipelines.

Research Focus

Key Achievements

1
H-Index
1
Papers
18
Total Citations
18
Avg Citations/Paper
🏆 Most Cited Paper
Development of a Fluorescent Ligand-Binding Assay Using the AcroWell Filter Plate
18 citations · 2000
📈 Most Prolific Year: 2000 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Purdue Pharma (Canada)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago